Pub Date : 2025-01-01DOI: 10.1016/j.rccl.2024.07.001
Francisco Buendía-Santiago, Antonio Meseguer-Hernández, José Manuel Andreu-Cayuelas, María del Carmen Guirao-Balsalobre, María del Rosario Mármol-Lozano, Juan Antonio Castillo-Moreno
{"title":"Indicación potencialmente alta de semaglutida en prevención secundaria en una región con alta prevalencia de obesidad","authors":"Francisco Buendía-Santiago, Antonio Meseguer-Hernández, José Manuel Andreu-Cayuelas, María del Carmen Guirao-Balsalobre, María del Rosario Mármol-Lozano, Juan Antonio Castillo-Moreno","doi":"10.1016/j.rccl.2024.07.001","DOIUrl":"10.1016/j.rccl.2024.07.001","url":null,"abstract":"","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 1","pages":"Pages 59-61"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141844937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.rccl.2024.07.004
Sergio Cinza-Sanjurjo , José Seijas-Amigo , Beatriz Fontela-Sánchez , Daniel Rey-Aldana , Paloma Sempere-Serrano , Pilar Mazón-Ramos , Diego Gabriel Mosteiro-Miguéns , Manuel Portela-Romero , Nerea Sánchez-Varela , Francisco Reyes-Santias , M. Teresa Ferreiro-Serrano , Mónica Barral-Carregal , Andrea Grela-Beiroa , Ana Suárez-Dios , Isabel Rego-Lijó , Jose Ramón González-Juanatey
Introduction and objectives
The management of cardiovascular risk factors (CVRF) should be conducted in Primary Care, which is particularly crucial for patients with prior cardiovascular disease. A semi-annual follow-up, aligned with the guidelines of clinical practice and coinciding with the administration of an injectable drug like inclisiran, could enhance healthcare efficiency. The CAPRICI study aims to analyze whether the implementation of a follow-up program, with semi-annual visits parallel to the administration of inclisiran in Primary Care, in patients with chronic ischemic heart disease, allows for optimized follow-up and improved control of CVRF.
Methods
The CAPRICI study is a randomized, controlled, prospective, multicenter trial involving 5 health centers in the Health Area of Santiago de Compostela and Barbanza: A Estrada, Concepción Arenal, Ribeira, Melide, and Milladoiro. The study will include patients with chronic coronary disease associated with other pathologies that increase cardiovascular risk, with elevated levels of low-density lipoprotein cholesterol (> 100 mg/dl) despite conventional treatment with high-potency statins, with or without ezetimibe. The number of visits to healthcare services, as well as the control of CVRF and lifestyle habits, will be recorded.
Conclusions
The results of this study will contribute to improving the knowledge about the care of patients at very high cardiovascular risk, particularly in optimizing the number of visits and hospital referrals, as well as in the control of their CVRF.
{"title":"Continuidad asistencial entre cardiología y AP en pacientes con cardiopatía isquémica crónica: diseño del estudio CAPRICI","authors":"Sergio Cinza-Sanjurjo , José Seijas-Amigo , Beatriz Fontela-Sánchez , Daniel Rey-Aldana , Paloma Sempere-Serrano , Pilar Mazón-Ramos , Diego Gabriel Mosteiro-Miguéns , Manuel Portela-Romero , Nerea Sánchez-Varela , Francisco Reyes-Santias , M. Teresa Ferreiro-Serrano , Mónica Barral-Carregal , Andrea Grela-Beiroa , Ana Suárez-Dios , Isabel Rego-Lijó , Jose Ramón González-Juanatey","doi":"10.1016/j.rccl.2024.07.004","DOIUrl":"10.1016/j.rccl.2024.07.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The management of cardiovascular risk factors (CVRF) should be conducted in Primary Care, which is particularly crucial for patients with prior cardiovascular disease. A semi-annual follow-up, aligned with the guidelines of clinical practice and coinciding with the administration of an injectable drug like inclisiran, could enhance healthcare efficiency. The CAPRICI study aims to analyze whether the implementation of a follow-up program, with semi-annual visits parallel to the administration of inclisiran in Primary Care, in patients with chronic ischemic heart disease, allows for optimized follow-up and improved control of CVRF.</div></div><div><h3>Methods</h3><div>The CAPRICI study is a randomized, controlled, prospective, multicenter trial involving 5 health centers in the Health Area of Santiago de Compostela and Barbanza: A Estrada, Concepción Arenal, Ribeira, Melide, and Milladoiro. The study will include patients with chronic coronary disease associated with other pathologies that increase cardiovascular risk, with elevated levels of low-density lipoprotein cholesterol (> 100 mg/dl) despite conventional treatment with high-potency statins, with or without ezetimibe. The number of visits to healthcare services, as well as the control of CVRF and lifestyle habits, will be recorded.</div></div><div><h3>Conclusions</h3><div>The results of this study will contribute to improving the knowledge about the care of patients at very high cardiovascular risk, particularly in optimizing the number of visits and hospital referrals, as well as in the control of their CVRF.</div><div>Clinicaltrials.gov identifier: <span><span>NCT06421363</span><svg><path></path></svg></span></div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 1","pages":"Pages 8-16"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143170424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.rccl.2024.07.002
Graciela Aurora Ruiz, Silvia Makhoul, Miguel Agustini, Vanina N. Gos Re, Sofía Maza, Julia Zarate, Paola Tombesi, Simon Salzberg
Introduction and objectives
Both ambulatory blood pressure monitoring (ABPM) and tilt-test (TT) can identify the hypotensive component that predisposes to syncope. The aim was to establish the prevalence of hypotension in ABPM and TT and to establish the concordance of the results between both methods.
Methods
Patients ≥ 18 years with syncope in whom it was decided to perform a TT (45 min at 75̊) were included. An ABPM was performed on different dates. The criteria of hypotension were: in TT, TT (+) or detection of systolic blood pressure ≤ 100 mmHg during the study, resulting from a drop respect to baseline systolic blood pressure; in ABPM, ≥ 2 falls ≥ 20 mmHg with respect to the previous one reaching systolic blood pressure ≤ 100 mmHg.
Results
A total of 61 patients were studied (62.5 ± 16.8 years, 39 women [64%]). TT was positive in 41% of the patients. Additionally, during TT, hypotension was detected in another 18% of patients and hypotension by ABPM was observed in the 51%. Combining both methods, hypotension was detected in 79% of the population (48 patients). Both studies were concordant in 32 patients (52%) (Cohen kappa index: 0.04). Hypotension was identified in 28% of patients only by TT and in 20% only by ABPM.
Conclusions
Using a strategy combining TT and ABPM, hypotension was detected in three quarters of this population with syncope. Both methods proved to be complementary not only to develop a diagnostic suspicion but also to guide the therapeutic management of these patients.
{"title":"Hipotensión en pacientes con síncope: prueba de basculación y monitorización de la presión arterial en la práctica clínica","authors":"Graciela Aurora Ruiz, Silvia Makhoul, Miguel Agustini, Vanina N. Gos Re, Sofía Maza, Julia Zarate, Paola Tombesi, Simon Salzberg","doi":"10.1016/j.rccl.2024.07.002","DOIUrl":"10.1016/j.rccl.2024.07.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Both ambulatory blood pressure monitoring (ABPM) and tilt-test (TT) can identify the hypotensive component that predisposes to syncope. The aim was to establish the prevalence of hypotension in ABPM and TT and to establish the concordance of the results between both methods.</div></div><div><h3>Methods</h3><div>Patients<!--> <!-->≥<!--> <!-->18 years with syncope in whom it was decided to perform a TT (45<!--> <!-->min at 75̊) were included. An ABPM was performed on different dates. The criteria of hypotension were: in TT, TT (+) or detection of systolic blood pressure<!--> <!-->≤<!--> <!-->100<!--> <!-->mmHg during the study, resulting from a drop respect to baseline systolic blood pressure; in ABPM, ≥<!--> <!-->2 falls<!--> <!-->≥<!--> <!-->20<!--> <!-->mmHg with respect to the previous one reaching systolic blood pressure<!--> <!-->≤<!--> <!-->100<!--> <!-->mmHg.</div></div><div><h3>Results</h3><div>A total of 61 patients were studied (62.5<!--> <!-->±<!--> <!-->16.8 years, 39 women [64%]). TT was positive in 41% of the patients. Additionally, during TT, hypotension was detected in another 18% of patients and hypotension by ABPM was observed in the 51%. Combining both methods, hypotension was detected in 79% of the population (48 patients). Both studies were concordant in 32 patients (52%) (Cohen kappa index: 0.04). Hypotension was identified in 28% of patients only by TT and in 20% only by ABPM.</div></div><div><h3>Conclusions</h3><div>Using a strategy combining TT and ABPM, hypotension was detected in three quarters of this population with syncope. Both methods proved to be complementary not only to develop a diagnostic suspicion but also to guide the therapeutic management of these patients.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 1","pages":"Pages 26-33"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143170426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.rccl.2024.07.008
M. José Ferreira-Díaz , Ana Laguía , Gabriela Topa
Introduction and objectives
Given the importance of cardiovascular disease, the leading cause of death in the world, and the fact that in Spain only 2–3% of the population can benefit from access to cardiac rehabilitation programs, the aim of this study is to consider the measurement of quality of life as a good indicator to determine the effectiveness of these programs. This longitudinal study evaluates the impact of a cardiac rehabilitation program on quality of life in a cohort of 181 patients at a Spanish hospital for 2 years.
Methods
Quality of life was assessed at four time points: on admission to the program, at discharge after 12 weeks, and at the 4- and 12-month revisions.
Results
The results show an increase in the perception of quality of life compared to the initial situation of the patients at the time of admission to the rehabilitation program, with positive results being observed in practically all the domains of the questionnaire, obtaining a higher score in the physical role domain.
Conclusions
This study shows that attendance at a cardiac rehabilitation program significantly improves self-perception of health, both physical and emotional.
{"title":"Improving quality of life through a cardiac rehabilitation program: a 4-wave longitudinal study","authors":"M. José Ferreira-Díaz , Ana Laguía , Gabriela Topa","doi":"10.1016/j.rccl.2024.07.008","DOIUrl":"10.1016/j.rccl.2024.07.008","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Given the importance of cardiovascular disease, the leading cause of death in the world, and the fact that in Spain only 2–3% of the population can benefit from access to cardiac rehabilitation programs, the aim of this study is to consider the measurement of quality of life as a good indicator to determine the effectiveness of these programs. This longitudinal study evaluates the impact of a cardiac rehabilitation program on quality of life in a cohort of 181 patients at a Spanish hospital for 2 years.</div></div><div><h3>Methods</h3><div>Quality of life was assessed at four time points: on admission to the program, at discharge after 12 weeks, and at the 4- and 12-month revisions.</div></div><div><h3>Results</h3><div>The results show an increase in the perception of quality of life compared to the initial situation of the patients at the time of admission to the rehabilitation program, with positive results being observed in practically all the domains of the questionnaire, obtaining a higher score in the physical role domain.</div></div><div><h3>Conclusions</h3><div>This study shows that attendance at a cardiac rehabilitation program significantly improves self-perception of health, both physical and emotional.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 1","pages":"Pages 34-42"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143171071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.rccl.2024.06.003
Tatiana Ramírez-Peña , David Corredor-Orlandelli , Daniel G. Fernández-Ávila , Ángel Alberto García , Óscar Muñoz-Velandia
Introduction and objectives
Proprotein convertase subtilisin/kexin type 9 convertase inhibitors (iPCSK9) effectively reduce low-density lipoprotein cholesterol and have been shown to decrease cardiovascular morbidity and mortality in high-risk patients. However, their cost hinders their real accessibility. This study seeks to describe variables related to iPCSK9 prescription in Colombia.
Methods
Population-based analysis of iPCSK9 prescriptions in Colombia during the years 2019-2021, based on data from the government database Sistema Integrado de Información de la Protección Social. Information was extracted on sex, age groups, geographical area (department), health regime, ICD-10 code and the professional profile of the prescriber.
Results
There were 7431 prescriptions, 49.5% for alirocumab and 50.5% for evolocumab. Most patients were men > 50 years old. The contributory regimen formulation was higher with a prescription rate ratio of 6.59 (95%CI, 6.147-7.073, P < .01). The most populated areas had the highest prescribing, while six departments had no prescriptions. The most common indications were dyslipidaemia and ischaemic heart disease, with cardiologists and internists being the main prescribers.
Conclusions
Formulation of iPCSK9 was lower than expected. There were more formulations in men and people > 50 years, data compatible with the higher incidence of cardiovascular disease in this population group. Regions with higher population density had more formulations and some areas, mainly rural, have no penetration. The marked differences in access between regions and regimens require further analysis to identify possible barriers to access.
前言和目的proprotein converting ase subtilisin/ keexin type 9 converase inhibitors （iPCSK9）能有效降低低密度脂蛋白胆固醇，并降低高危患者心血管疾病的发病率和死亡率。然而，它们的成本阻碍了它们真正的可访问性。本研究旨在描述与哥伦比亚iPCSK9处方相关的变量。方法基于政府数据库Sistema Integrado de Información de la Protección Social的数据，对哥伦比亚2019-2021年iPCSK9处方进行基于人群的分析。提取了关于性别、年龄组、地理区域（部门）、保健制度、ICD-10代码和开处方者专业概况的信息。结果共有7431张处方，其中alirocumab占49.5%，evolocumab占50.5%。大多数患者为男性；50岁了。贡献方案的处方率比更高，为6.59 (95%CI, 6.147 ~ 7.073, P <；. 01)。人口最密集地区处方最高，6个科室无处方。最常见的适应症是血脂异常和缺血性心脏病，心脏病专家和内科医生是主要的开处方者。结论iPCSK9的处方量低于预期。男性和女性的配方更多。50年来，数据与这一人群心血管疾病发病率较高相符。人口密度高的地区配方更多，一些地区（主要是农村）没有渗透率。需要进一步分析各区域和各治疗方案在获取方面的显著差异，以确定可能存在的获取障碍。
{"title":"Frecuencia y distribución geográfica de la prescripción de inhibidores de PCSK9 en Colombia entre 2019 y 2021","authors":"Tatiana Ramírez-Peña , David Corredor-Orlandelli , Daniel G. Fernández-Ávila , Ángel Alberto García , Óscar Muñoz-Velandia","doi":"10.1016/j.rccl.2024.06.003","DOIUrl":"10.1016/j.rccl.2024.06.003","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Proprotein convertase subtilisin/kexin type<!--> <!-->9 convertase inhibitors (iPCSK9) effectively reduce low-density lipoprotein cholesterol and have been shown to decrease cardiovascular morbidity and mortality in high-risk patients. However, their cost hinders their real accessibility. This study seeks to describe variables related to iPCSK9 prescription in Colombia.</div></div><div><h3>Methods</h3><div>Population-based analysis of iPCSK9 prescriptions in Colombia during the years 2019-2021, based on data from the government database <em>Sistema Integrado de Información de la Protección Social</em>. Information was extracted on sex, age groups, geographical area (department), health regime, ICD-10 code and the professional profile of the prescriber.</div></div><div><h3>Results</h3><div>There were 7431 prescriptions, 49.5% for alirocumab and 50.5% for evolocumab. Most patients were men ><!--> <!-->50<!--> <!-->years old. The contributory regimen formulation was higher with a prescription rate ratio of 6.59 (95%CI, 6.147-7.073, <em>P</em> <!--><<!--> <!-->.01). The most populated areas had the highest prescribing, while six departments had no prescriptions. The most common indications were dyslipidaemia and ischaemic heart disease, with cardiologists and internists being the main prescribers.</div></div><div><h3>Conclusions</h3><div>Formulation of iPCSK9 was lower than expected. There were more formulations in men and people ><!--> <!-->50<!--> <!-->years, data compatible with the higher incidence of cardiovascular disease in this population group. Regions with higher population density had more formulations and some areas, mainly rural, have no penetration. The marked differences in access between regions and regimens require further analysis to identify possible barriers to access.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 1","pages":"Pages 17-25"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.rccl.2024.04.001
Diana Isabel Katekaru-Tokeshi , Félix Alonso Revilla-Manchego , Luz Marilyn Vásquez-Salazar , Moisés Jiménez-Santos
{"title":"Leiomiomatosis intravenosa con extensión intracardiaca y a la arteria pulmonar","authors":"Diana Isabel Katekaru-Tokeshi , Félix Alonso Revilla-Manchego , Luz Marilyn Vásquez-Salazar , Moisés Jiménez-Santos","doi":"10.1016/j.rccl.2024.04.001","DOIUrl":"10.1016/j.rccl.2024.04.001","url":null,"abstract":"","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 1","pages":"Pages 65-66"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.rccl.2024.07.006
Danilo Weir-Restrepo , María Antonia Mesa-Maya , María Isabel Carvajal-Vélez , Pedro Abad-Díaz , Laura Duque-González
The quadricuspid aortic valve (QAV) is a rare congenital heart defect characterized by the presence of 4 cusps in the aortic valve structure. It is frequently associated with other congenital heart defects. Patients are usually asymptomatic, but when this condition is associated with functional disorders such as aortic regurgitation or stenosis, clinical manifestations are evident. The final diagnosis is made using different cardiac imaging techniques such as echocardiography, cardiac tomography, and nuclear magnetic resonance.
The treatment of this condition depends on the functionality of the aortic valve, and accordingly will be the indication for surgical treatment. The prognosis is generally favorable and depends on the functional compromise of the valve.
{"title":"Válvula aórtica cuadricúspide: una revisión de la literatura","authors":"Danilo Weir-Restrepo , María Antonia Mesa-Maya , María Isabel Carvajal-Vélez , Pedro Abad-Díaz , Laura Duque-González","doi":"10.1016/j.rccl.2024.07.006","DOIUrl":"10.1016/j.rccl.2024.07.006","url":null,"abstract":"<div><div>The quadricuspid aortic valve (QAV) is a rare congenital heart defect characterized by the presence of 4 cusps in the aortic valve structure. It is frequently associated with other congenital heart defects. Patients are usually asymptomatic, but when this condition is associated with functional disorders such as aortic regurgitation or stenosis, clinical manifestations are evident. The final diagnosis is made using different cardiac imaging techniques such as echocardiography, cardiac tomography, and nuclear magnetic resonance.</div><div>The treatment of this condition depends on the functionality of the aortic valve, and accordingly will be the indication for surgical treatment. The prognosis is generally favorable and depends on the functional compromise of the valve.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 1","pages":"Pages 53-58"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143171070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.rccl.2024.09.002
Álvaro Lorente Ros , Sonia Antoñana Ugalde , Álvaro Izquierdo Bajo , Luna Carrillo Alemán
Environmental pollution profoundly affects cardiovascular health. Traditionally, recommendations on cardiovascular disease (CVD) prevention focus on modifiable behavioral and metabolic risk factors, but environmental pollution is emerging as a critical factor, causing up to 20% of cardiovascular mortality.
This review explores the impact of environmental factors on cardiovascular health, examining the evidence on contaminants such as microplastics, atmospheric and acoustic pollution, and exposure to heavy metals. It evaluates their influence on the development of cardiovascular disease and their association with increased mortality, as well as their interaction with traditional risk factors. Addressing environmental pollution is not only crucial for CVD prevention, but also an ethical imperative. A holistic approach that considers both traditional and environmental risk factors is crucial for designing effective public health strategies and addressing the ethical dimension inherent in the protection of human health and the environment.
{"title":"Contaminación ambiental y salud cardiovascular: enfoque integral y nuevas evidencias","authors":"Álvaro Lorente Ros , Sonia Antoñana Ugalde , Álvaro Izquierdo Bajo , Luna Carrillo Alemán","doi":"10.1016/j.rccl.2024.09.002","DOIUrl":"10.1016/j.rccl.2024.09.002","url":null,"abstract":"<div><div>Environmental pollution profoundly affects cardiovascular health. Traditionally, recommendations on cardiovascular disease (CVD) prevention focus on modifiable behavioral and metabolic risk factors, but environmental pollution is emerging as a critical factor, causing up to 20% of cardiovascular mortality.</div><div>This review explores the impact of environmental factors on cardiovascular health, examining the evidence on contaminants such as microplastics, atmospheric and acoustic pollution, and exposure to heavy metals. It evaluates their influence on the development of cardiovascular disease and their association with increased mortality, as well as their interaction with traditional risk factors. Addressing environmental pollution is not only crucial for CVD prevention, but also an ethical imperative. A holistic approach that considers both traditional and environmental risk factors is crucial for designing effective public health strategies and addressing the ethical dimension inherent in the protection of human health and the environment.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 ","pages":"Pages 3-11"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号